IVERIC bio’s Avacincaptad Pegol Receives Breakthrough Therapy Status from FDA for Geographic Atrophy Treatment
IVERIC bio, Inc. announces U.S. FDA Breakthrough Therapy designation for avacincaptad pegol (Zimura®), a novel investigational complement C5 inhibitor for treating Geographic atrophy (GA) secondary to ...